Thus, this study aims to evaluate polytherapy using LASSBio-1971 and the dual PI3K/mTOR inhibitor PKI-587 to bypass tumor resistance mechanisms, accessing the synergist effect and the mechanisms of action of the polytherapy by flanking different cellular pathways involved in GB biology. This evidence concerns the gene MTOR and neoplasm.